▶ 調査レポート

半固形製剤のグローバル市場インサイト・予測(~2028年)

• 英文タイトル:Global Semi-Solid Dosage Form Market Insights, Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。半固形製剤のグローバル市場インサイト・予測(~2028年) / Global Semi-Solid Dosage Form Market Insights, Forecast to 2028 / QY2203B13277資料のイメージです。• レポートコード:QY2203B13277
• 出版社/出版日:QYResearch / 2022年3月
• レポート形態:英文、PDF、127ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥686,000 (USD4,900)▷ お問い合わせ
  Multi User¥1,029,000 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,372,000 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界の半固形製剤の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に半固形製剤の世界市場のxxx%を占める「軟膏」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「皮膚」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国の半固形製剤の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの半固形製剤市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの半固形製剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

半固形製剤のグローバル主要メーカーには、Johnson & Johnson、Merck & Co、Bayer AG、Hisamitsu Pharmaceutical、Glenmark Pharmaceuticals、Cipla Ltd、Nestlé SA、Novartis AG、GlaxoSmithKline plc、Bausch Health Companies、Allergan plc、Biofrontera, Inc.、Crown Laboratories Inc.、Akorn Inc. (US)、Ingenus Pharmaceuticals、Sun Pharmaceuticals、Crescita Therapeutics Inc.、Mylan N.V.、Encore Dermatology, Inc.、LEO Pharma、Almirall, S.A、Aclaris Therapeutics, Inc.、Taro Pharmaceutical Industries Ltd.、Teligent Pharma、Perrigo Pharmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

半固形製剤市場は、種類と用途によって区分されます。世界の半固形製剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
軟膏、ゲル、その他

【用途別セグメント】
皮膚、鼻腔、膣、直腸腔、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 半固形製剤製品概要
- 種類別市場(軟膏、ゲル、その他)
- 用途別市場(皮膚、鼻腔、膣、直腸腔、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の半固形製剤販売量予測2017-2028
- 世界の半固形製剤売上予測2017-2028
- 半固形製剤の地域別販売量
- 半固形製剤の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別半固形製剤販売量
- 主要メーカー別半固形製剤売上
- 主要メーカー別半固形製剤価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(軟膏、ゲル、その他)
- 半固形製剤の種類別販売量
- 半固形製剤の種類別売上
- 半固形製剤の種類別価格
・用途別市場規模(皮膚、鼻腔、膣、直腸腔、その他)
- 半固形製剤の用途別販売量
- 半固形製剤の用途別売上
- 半固形製剤の用途別価格
・北米市場
- 北米の半固形製剤市場規模(種類別、用途別)
- 主要国別の半固形製剤市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの半固形製剤市場規模(種類別、用途別)
- 主要国別の半固形製剤市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の半固形製剤市場規模(種類別、用途別)
- 主要国別の半固形製剤市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の半固形製剤市場規模(種類別、用途別)
- 主要国別の半固形製剤市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの半固形製剤市場規模(種類別、用途別)
- 主要国別の半固形製剤市場規模(トルコ、サウジアラビア)
・企業情報
Johnson & Johnson、Merck & Co、Bayer AG、Hisamitsu Pharmaceutical、Glenmark Pharmaceuticals、Cipla Ltd、Nestlé SA、Novartis AG、GlaxoSmithKline plc、Bausch Health Companies、Allergan plc、Biofrontera, Inc.、Crown Laboratories Inc.、Akorn Inc. (US)、Ingenus Pharmaceuticals、Sun Pharmaceuticals、Crescita Therapeutics Inc.、Mylan N.V.、Encore Dermatology, Inc.、LEO Pharma、Almirall, S.A、Aclaris Therapeutics, Inc.、Taro Pharmaceutical Industries Ltd.、Teligent Pharma、Perrigo Pharma
・産業チェーン及び販売チャネル分析
- 半固形製剤の産業チェーン分析
- 半固形製剤の原材料
- 半固形製剤の生産プロセス
- 半固形製剤の販売及びマーケティング
- 半固形製剤の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 半固形製剤の産業動向
- 半固形製剤のマーケットドライバー
- 半固形製剤の課題
- 半固形製剤の阻害要因
・主な調査結果

Market Analysis and Insights: Global Semi-Solid Dosage Form Market
Due to the COVID-19 pandemic, the global Semi-Solid Dosage Form market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Ointments accounting for % of the Semi-Solid Dosage Form global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Skin segment is altered to an % CAGR throughout this forecast period.
China Semi-Solid Dosage Form market size is valued at US$ million in 2021, while the US and Europe Semi-Solid Dosage Form are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Semi-Solid Dosage Form landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Semi-Solid Dosage Form include Johnson & Johnson, Merck & Co, Bayer AG, Hisamitsu Pharmaceutical, Glenmark Pharmaceuticals, Cipla Ltd, Nestlé SA, Novartis AG and GlaxoSmithKline plc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Semi-Solid Dosage Form Scope and Segment
Semi-Solid Dosage Form market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Semi-Solid Dosage Form market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Ointments
Gels
Others
Segment by Application
Skin
Nasal Cavity
Vaginal Cavity
Rectal Cavity
Others
By Company
Johnson & Johnson
Merck & Co
Bayer AG
Hisamitsu Pharmaceutical
Glenmark Pharmaceuticals
Cipla Ltd
Nestlé SA
Novartis AG
GlaxoSmithKline plc
Bausch Health Companies
Allergan plc
Biofrontera, Inc.
Crown Laboratories Inc.
Akorn Inc. (US)
Ingenus Pharmaceuticals
Sun Pharmaceuticals
Crescita Therapeutics Inc.
Mylan N.V.
Encore Dermatology, Inc.
LEO Pharma
Almirall, S.A
Aclaris Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Perrigo Pharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

1 Study Coverage
1.1 Semi-Solid Dosage Form Product Introduction
1.2 Market by Type
1.2.1 Global Semi-Solid Dosage Form Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Ointments
1.2.3 Gels
1.2.4 Others
1.3 Market by Application
1.3.1 Global Semi-Solid Dosage Form Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Skin
1.3.3 Nasal Cavity
1.3.4 Vaginal Cavity
1.3.5 Rectal Cavity
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Semi-Solid Dosage Form Sales Estimates and Forecasts 2017-2028
2.2 Global Semi-Solid Dosage Form Revenue Estimates and Forecasts 2017-2028
2.3 Global Semi-Solid Dosage Form Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Semi-Solid Dosage Form Sales by Region
2.4.1 Global Semi-Solid Dosage Form Sales by Region (2017-2022)
2.4.2 Global Sales Semi-Solid Dosage Form by Region (2023-2028)
2.5 Global Semi-Solid Dosage Form Revenue by Region
2.5.1 Global Semi-Solid Dosage Form Revenue by Region (2017-2022)
2.5.2 Global Semi-Solid Dosage Form Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Semi-Solid Dosage Form Sales by Manufacturers
3.1.1 Global Top Semi-Solid Dosage Form Manufacturers by Sales (2017-2022)
3.1.2 Global Semi-Solid Dosage Form Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Semi-Solid Dosage Form in 2021
3.2 Global Semi-Solid Dosage Form Revenue by Manufacturers
3.2.1 Global Semi-Solid Dosage Form Revenue by Manufacturers (2017-2022)
3.2.2 Global Semi-Solid Dosage Form Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Semi-Solid Dosage Form Revenue in 2021
3.3 Global Semi-Solid Dosage Form Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Semi-Solid Dosage Form Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Semi-Solid Dosage Form Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Semi-Solid Dosage Form Sales by Type
4.1.1 Global Semi-Solid Dosage Form Historical Sales by Type (2017-2022)
4.1.2 Global Semi-Solid Dosage Form Forecasted Sales by Type (2023-2028)
4.1.3 Global Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
4.2 Global Semi-Solid Dosage Form Revenue by Type
4.2.1 Global Semi-Solid Dosage Form Historical Revenue by Type (2017-2022)
4.2.2 Global Semi-Solid Dosage Form Forecasted Revenue by Type (2023-2028)
4.2.3 Global Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
4.3 Global Semi-Solid Dosage Form Price by Type
4.3.1 Global Semi-Solid Dosage Form Price by Type (2017-2022)
4.3.2 Global Semi-Solid Dosage Form Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Semi-Solid Dosage Form Sales by Application
5.1.1 Global Semi-Solid Dosage Form Historical Sales by Application (2017-2022)
5.1.2 Global Semi-Solid Dosage Form Forecasted Sales by Application (2023-2028)
5.1.3 Global Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
5.2 Global Semi-Solid Dosage Form Revenue by Application
5.2.1 Global Semi-Solid Dosage Form Historical Revenue by Application (2017-2022)
5.2.2 Global Semi-Solid Dosage Form Forecasted Revenue by Application (2023-2028)
5.2.3 Global Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
5.3 Global Semi-Solid Dosage Form Price by Application
5.3.1 Global Semi-Solid Dosage Form Price by Application (2017-2022)
5.3.2 Global Semi-Solid Dosage Form Price Forecast by Application (2023-2028)
6 North America
6.1 North America Semi-Solid Dosage Form Market Size by Type
6.1.1 North America Semi-Solid Dosage Form Sales by Type (2017-2028)
6.1.2 North America Semi-Solid Dosage Form Revenue by Type (2017-2028)
6.2 North America Semi-Solid Dosage Form Market Size by Application
6.2.1 North America Semi-Solid Dosage Form Sales by Application (2017-2028)
6.2.2 North America Semi-Solid Dosage Form Revenue by Application (2017-2028)
6.3 North America Semi-Solid Dosage Form Market Size by Country
6.3.1 North America Semi-Solid Dosage Form Sales by Country (2017-2028)
6.3.2 North America Semi-Solid Dosage Form Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Semi-Solid Dosage Form Market Size by Type
7.1.1 Europe Semi-Solid Dosage Form Sales by Type (2017-2028)
7.1.2 Europe Semi-Solid Dosage Form Revenue by Type (2017-2028)
7.2 Europe Semi-Solid Dosage Form Market Size by Application
7.2.1 Europe Semi-Solid Dosage Form Sales by Application (2017-2028)
7.2.2 Europe Semi-Solid Dosage Form Revenue by Application (2017-2028)
7.3 Europe Semi-Solid Dosage Form Market Size by Country
7.3.1 Europe Semi-Solid Dosage Form Sales by Country (2017-2028)
7.3.2 Europe Semi-Solid Dosage Form Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Semi-Solid Dosage Form Market Size by Type
8.1.1 Asia Pacific Semi-Solid Dosage Form Sales by Type (2017-2028)
8.1.2 Asia Pacific Semi-Solid Dosage Form Revenue by Type (2017-2028)
8.2 Asia Pacific Semi-Solid Dosage Form Market Size by Application
8.2.1 Asia Pacific Semi-Solid Dosage Form Sales by Application (2017-2028)
8.2.2 Asia Pacific Semi-Solid Dosage Form Revenue by Application (2017-2028)
8.3 Asia Pacific Semi-Solid Dosage Form Market Size by Region
8.3.1 Asia Pacific Semi-Solid Dosage Form Sales by Region (2017-2028)
8.3.2 Asia Pacific Semi-Solid Dosage Form Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Semi-Solid Dosage Form Market Size by Type
9.1.1 Latin America Semi-Solid Dosage Form Sales by Type (2017-2028)
9.1.2 Latin America Semi-Solid Dosage Form Revenue by Type (2017-2028)
9.2 Latin America Semi-Solid Dosage Form Market Size by Application
9.2.1 Latin America Semi-Solid Dosage Form Sales by Application (2017-2028)
9.2.2 Latin America Semi-Solid Dosage Form Revenue by Application (2017-2028)
9.3 Latin America Semi-Solid Dosage Form Market Size by Country
9.3.1 Latin America Semi-Solid Dosage Form Sales by Country (2017-2028)
9.3.2 Latin America Semi-Solid Dosage Form Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Semi-Solid Dosage Form Market Size by Type
10.1.1 Middle East and Africa Semi-Solid Dosage Form Sales by Type (2017-2028)
10.1.2 Middle East and Africa Semi-Solid Dosage Form Revenue by Type (2017-2028)
10.2 Middle East and Africa Semi-Solid Dosage Form Market Size by Application
10.2.1 Middle East and Africa Semi-Solid Dosage Form Sales by Application (2017-2028)
10.2.2 Middle East and Africa Semi-Solid Dosage Form Revenue by Application (2017-2028)
10.3 Middle East and Africa Semi-Solid Dosage Form Market Size by Country
10.3.1 Middle East and Africa Semi-Solid Dosage Form Sales by Country (2017-2028)
10.3.2 Middle East and Africa Semi-Solid Dosage Form Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Overview
11.1.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Johnson & Johnson Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Johnson & Johnson Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Corporation Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck & Co Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck & Co Recent Developments
11.3 Bayer AG
11.3.1 Bayer AG Corporation Information
11.3.2 Bayer AG Overview
11.3.3 Bayer AG Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bayer AG Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bayer AG Recent Developments
11.4 Hisamitsu Pharmaceutical
11.4.1 Hisamitsu Pharmaceutical Corporation Information
11.4.2 Hisamitsu Pharmaceutical Overview
11.4.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Hisamitsu Pharmaceutical Recent Developments
11.5 Glenmark Pharmaceuticals
11.5.1 Glenmark Pharmaceuticals Corporation Information
11.5.2 Glenmark Pharmaceuticals Overview
11.5.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Glenmark Pharmaceuticals Recent Developments
11.6 Cipla Ltd
11.6.1 Cipla Ltd Corporation Information
11.6.2 Cipla Ltd Overview
11.6.3 Cipla Ltd Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Cipla Ltd Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Cipla Ltd Recent Developments
11.7 Nestlé SA
11.7.1 Nestlé SA Corporation Information
11.7.2 Nestlé SA Overview
11.7.3 Nestlé SA Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Nestlé SA Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Nestlé SA Recent Developments
11.8 Novartis AG
11.8.1 Novartis AG Corporation Information
11.8.2 Novartis AG Overview
11.8.3 Novartis AG Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Novartis AG Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis AG Recent Developments
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Corporation Information
11.9.2 GlaxoSmithKline plc Overview
11.9.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 GlaxoSmithKline plc Recent Developments
11.10 Bausch Health Companies
11.10.1 Bausch Health Companies Corporation Information
11.10.2 Bausch Health Companies Overview
11.10.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Bausch Health Companies Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Bausch Health Companies Recent Developments
11.11 Allergan plc
11.11.1 Allergan plc Corporation Information
11.11.2 Allergan plc Overview
11.11.3 Allergan plc Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Allergan plc Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Allergan plc Recent Developments
11.12 Biofrontera, Inc.
11.12.1 Biofrontera, Inc. Corporation Information
11.12.2 Biofrontera, Inc. Overview
11.12.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Biofrontera, Inc. Recent Developments
11.13 Crown Laboratories Inc.
11.13.1 Crown Laboratories Inc. Corporation Information
11.13.2 Crown Laboratories Inc. Overview
11.13.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Crown Laboratories Inc. Recent Developments
11.14 Akorn Inc. (US)
11.14.1 Akorn Inc. (US) Corporation Information
11.14.2 Akorn Inc. (US) Overview
11.14.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Akorn Inc. (US) Recent Developments
11.15 Ingenus Pharmaceuticals
11.15.1 Ingenus Pharmaceuticals Corporation Information
11.15.2 Ingenus Pharmaceuticals Overview
11.15.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Ingenus Pharmaceuticals Recent Developments
11.16 Sun Pharmaceuticals
11.16.1 Sun Pharmaceuticals Corporation Information
11.16.2 Sun Pharmaceuticals Overview
11.16.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Sun Pharmaceuticals Recent Developments
11.17 Crescita Therapeutics Inc.
11.17.1 Crescita Therapeutics Inc. Corporation Information
11.17.2 Crescita Therapeutics Inc. Overview
11.17.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Crescita Therapeutics Inc. Recent Developments
11.18 Mylan N.V.
11.18.1 Mylan N.V. Corporation Information
11.18.2 Mylan N.V. Overview
11.18.3 Mylan N.V. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Mylan N.V. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Mylan N.V. Recent Developments
11.19 Encore Dermatology, Inc.
11.19.1 Encore Dermatology, Inc. Corporation Information
11.19.2 Encore Dermatology, Inc. Overview
11.19.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Encore Dermatology, Inc. Recent Developments
11.20 LEO Pharma
11.20.1 LEO Pharma Corporation Information
11.20.2 LEO Pharma Overview
11.20.3 LEO Pharma Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 LEO Pharma Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 LEO Pharma Recent Developments
11.21 Almirall, S.A
11.21.1 Almirall, S.A Corporation Information
11.21.2 Almirall, S.A Overview
11.21.3 Almirall, S.A Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Almirall, S.A Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Almirall, S.A Recent Developments
11.22 Aclaris Therapeutics, Inc.
11.22.1 Aclaris Therapeutics, Inc. Corporation Information
11.22.2 Aclaris Therapeutics, Inc. Overview
11.22.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Aclaris Therapeutics, Inc. Recent Developments
11.23 Taro Pharmaceutical Industries Ltd.
11.23.1 Taro Pharmaceutical Industries Ltd. Corporation Information
11.23.2 Taro Pharmaceutical Industries Ltd. Overview
11.23.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Taro Pharmaceutical Industries Ltd. Recent Developments
11.24 Teligent Pharma
11.24.1 Teligent Pharma Corporation Information
11.24.2 Teligent Pharma Overview
11.24.3 Teligent Pharma Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 Teligent Pharma Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 Teligent Pharma Recent Developments
11.25 Perrigo Pharma
11.25.1 Perrigo Pharma Corporation Information
11.25.2 Perrigo Pharma Overview
11.25.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Perrigo Pharma Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Perrigo Pharma Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Semi-Solid Dosage Form Industry Chain Analysis
12.2 Semi-Solid Dosage Form Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Semi-Solid Dosage Form Production Mode & Process
12.4 Semi-Solid Dosage Form Sales and Marketing
12.4.1 Semi-Solid Dosage Form Sales Channels
12.4.2 Semi-Solid Dosage Form Distributors
12.5 Semi-Solid Dosage Form Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Semi-Solid Dosage Form Industry Trends
13.2 Semi-Solid Dosage Form Market Drivers
13.3 Semi-Solid Dosage Form Market Challenges
13.4 Semi-Solid Dosage Form Market Restraints
14 Key Findings in The Global Semi-Solid Dosage Form Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Semi-Solid Dosage Form Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Ointments
Table 3. Major Manufacturers of Gels
Table 4. Major Manufacturers of Others
Table 5. Global Semi-Solid Dosage Form Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Semi-Solid Dosage Form Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Semi-Solid Dosage Form Sales by Region (2017-2022) & (K Units)
Table 8. Global Semi-Solid Dosage Form Sales Market Share by Region (2017-2022)
Table 9. Global Semi-Solid Dosage Form Sales by Region (2023-2028) & (K Units)
Table 10. Global Semi-Solid Dosage Form Sales Market Share by Region (2023-2028)
Table 11. Global Semi-Solid Dosage Form Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Semi-Solid Dosage Form Revenue Market Share by Region (2017-2022)
Table 13. Global Semi-Solid Dosage Form Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Semi-Solid Dosage Form Revenue Market Share by Region (2023-2028)
Table 15. Global Semi-Solid Dosage Form Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Semi-Solid Dosage Form Sales Share by Manufacturers (2017-2022)
Table 17. Global Semi-Solid Dosage Form Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Semi-Solid Dosage Form Revenue Share by Manufacturers (2017-2022)
Table 19. Semi-Solid Dosage Form Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Semi-Solid Dosage Form Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Semi-Solid Dosage Form by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Semi-Solid Dosage Form as of 2021)
Table 22. Semi-Solid Dosage Form Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Semi-Solid Dosage Form Product Offered
Table 24. Date of Manufacturers Enter into Semi-Solid Dosage Form Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Semi-Solid Dosage Form Sales by Type (2017-2022) & (K Units)
Table 27. Global Semi-Solid Dosage Form Sales by Type (2023-2028) & (K Units)
Table 28. Global Semi-Solid Dosage Form Sales Share by Type (2017-2022)
Table 29. Global Semi-Solid Dosage Form Sales Share by Type (2023-2028)
Table 30. Global Semi-Solid Dosage Form Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Semi-Solid Dosage Form Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Semi-Solid Dosage Form Revenue Share by Type (2017-2022)
Table 33. Global Semi-Solid Dosage Form Revenue Share by Type (2023-2028)
Table 34. Semi-Solid Dosage Form Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Semi-Solid Dosage Form Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Semi-Solid Dosage Form Sales by Application (2017-2022) & (K Units)
Table 37. Global Semi-Solid Dosage Form Sales by Application (2023-2028) & (K Units)
Table 38. Global Semi-Solid Dosage Form Sales Share by Application (2017-2022)
Table 39. Global Semi-Solid Dosage Form Sales Share by Application (2023-2028)
Table 40. Global Semi-Solid Dosage Form Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Semi-Solid Dosage Form Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Semi-Solid Dosage Form Revenue Share by Application (2017-2022)
Table 43. Global Semi-Solid Dosage Form Revenue Share by Application (2023-2028)
Table 44. Semi-Solid Dosage Form Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Semi-Solid Dosage Form Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America Semi-Solid Dosage Form Sales by Type (2017-2022) & (K Units)
Table 47. North America Semi-Solid Dosage Form Sales by Type (2023-2028) & (K Units)
Table 48. North America Semi-Solid Dosage Form Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Semi-Solid Dosage Form Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Semi-Solid Dosage Form Sales by Application (2017-2022) & (K Units)
Table 51. North America Semi-Solid Dosage Form Sales by Application (2023-2028) & (K Units)
Table 52. North America Semi-Solid Dosage Form Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Semi-Solid Dosage Form Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Semi-Solid Dosage Form Sales by Country (2017-2022) & (K Units)
Table 55. North America Semi-Solid Dosage Form Sales by Country (2023-2028) & (K Units)
Table 56. North America Semi-Solid Dosage Form Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Semi-Solid Dosage Form Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Semi-Solid Dosage Form Sales by Type (2017-2022) & (K Units)
Table 59. Europe Semi-Solid Dosage Form Sales by Type (2023-2028) & (K Units)
Table 60. Europe Semi-Solid Dosage Form Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Semi-Solid Dosage Form Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Semi-Solid Dosage Form Sales by Application (2017-2022) & (K Units)
Table 63. Europe Semi-Solid Dosage Form Sales by Application (2023-2028) & (K Units)
Table 64. Europe Semi-Solid Dosage Form Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Semi-Solid Dosage Form Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Semi-Solid Dosage Form Sales by Country (2017-2022) & (K Units)
Table 67. Europe Semi-Solid Dosage Form Sales by Country (2023-2028) & (K Units)
Table 68. Europe Semi-Solid Dosage Form Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Semi-Solid Dosage Form Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Semi-Solid Dosage Form Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Semi-Solid Dosage Form Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Semi-Solid Dosage Form Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Semi-Solid Dosage Form Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Semi-Solid Dosage Form Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Semi-Solid Dosage Form Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Semi-Solid Dosage Form Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Semi-Solid Dosage Form Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Semi-Solid Dosage Form Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Semi-Solid Dosage Form Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Semi-Solid Dosage Form Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Semi-Solid Dosage Form Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Semi-Solid Dosage Form Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Semi-Solid Dosage Form Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Semi-Solid Dosage Form Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Semi-Solid Dosage Form Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Semi-Solid Dosage Form Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Semi-Solid Dosage Form Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Semi-Solid Dosage Form Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Semi-Solid Dosage Form Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Semi-Solid Dosage Form Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Semi-Solid Dosage Form Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Semi-Solid Dosage Form Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Semi-Solid Dosage Form Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Semi-Solid Dosage Form Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Semi-Solid Dosage Form Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Semi-Solid Dosage Form Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Semi-Solid Dosage Form Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Semi-Solid Dosage Form Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Semi-Solid Dosage Form Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Semi-Solid Dosage Form Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Semi-Solid Dosage Form Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Semi-Solid Dosage Form Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Semi-Solid Dosage Form Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Semi-Solid Dosage Form Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Semi-Solid Dosage Form Revenue by Country (2023-2028) & (US$ Million)
Table 106. Johnson & Johnson Corporation Information
Table 107. Johnson & Johnson Description and Major Businesses
Table 108. Johnson & Johnson Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Johnson & Johnson Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Johnson & Johnson Recent Developments
Table 111. Merck & Co Corporation Information
Table 112. Merck & Co Description and Major Businesses
Table 113. Merck & Co Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Merck & Co Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Merck & Co Recent Developments
Table 116. Bayer AG Corporation Information
Table 117. Bayer AG Description and Major Businesses
Table 118. Bayer AG Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Bayer AG Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Bayer AG Recent Developments
Table 121. Hisamitsu Pharmaceutical Corporation Information
Table 122. Hisamitsu Pharmaceutical Description and Major Businesses
Table 123. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Hisamitsu Pharmaceutical Recent Developments
Table 126. Glenmark Pharmaceuticals Corporation Information
Table 127. Glenmark Pharmaceuticals Description and Major Businesses
Table 128. Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Glenmark Pharmaceuticals Recent Developments
Table 131. Cipla Ltd Corporation Information
Table 132. Cipla Ltd Description and Major Businesses
Table 133. Cipla Ltd Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Cipla Ltd Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Cipla Ltd Recent Developments
Table 136. Nestlé SA Corporation Information
Table 137. Nestlé SA Description and Major Businesses
Table 138. Nestlé SA Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Nestlé SA Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Nestlé SA Recent Developments
Table 141. Novartis AG Corporation Information
Table 142. Novartis AG Description and Major Businesses
Table 143. Novartis AG Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. Novartis AG Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Novartis AG Recent Developments
Table 146. GlaxoSmithKline plc Corporation Information
Table 147. GlaxoSmithKline plc Description and Major Businesses
Table 148. GlaxoSmithKline plc Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. GlaxoSmithKline plc Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. GlaxoSmithKline plc Recent Developments
Table 151. Bausch Health Companies Corporation Information
Table 152. Bausch Health Companies Description and Major Businesses
Table 153. Bausch Health Companies Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 154. Bausch Health Companies Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Bausch Health Companies Recent Developments
Table 156. Allergan plc Corporation Information
Table 157. Allergan plc Description and Major Businesses
Table 158. Allergan plc Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 159. Allergan plc Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Allergan plc Recent Developments
Table 161. Biofrontera, Inc. Corporation Information
Table 162. Biofrontera, Inc. Description and Major Businesses
Table 163. Biofrontera, Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 164. Biofrontera, Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Biofrontera, Inc. Recent Developments
Table 166. Crown Laboratories Inc. Corporation Information
Table 167. Crown Laboratories Inc. Description and Major Businesses
Table 168. Crown Laboratories Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 169. Crown Laboratories Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Crown Laboratories Inc. Recent Developments
Table 171. Akorn Inc. (US) Corporation Information
Table 172. Akorn Inc. (US) Description and Major Businesses
Table 173. Akorn Inc. (US) Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 174. Akorn Inc. (US) Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Akorn Inc. (US) Recent Developments
Table 176. Ingenus Pharmaceuticals Corporation Information
Table 177. Ingenus Pharmaceuticals Description and Major Businesses
Table 178. Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 179. Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. Ingenus Pharmaceuticals Recent Developments
Table 181. Sun Pharmaceuticals Corporation Information
Table 182. Sun Pharmaceuticals Description and Major Businesses
Table 183. Sun Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 184. Sun Pharmaceuticals Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. Sun Pharmaceuticals Recent Developments
Table 186. Crescita Therapeutics Inc. Corporation Information
Table 187. Crescita Therapeutics Inc. Description and Major Businesses
Table 188. Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 189. Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. Crescita Therapeutics Inc. Recent Developments
Table 191. Mylan N.V. Corporation Information
Table 192. Mylan N.V. Description and Major Businesses
Table 193. Mylan N.V. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 194. Mylan N.V. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 195. Mylan N.V. Recent Developments
Table 196. Encore Dermatology, Inc. Corporation Information
Table 197. Encore Dermatology, Inc. Description and Major Businesses
Table 198. Encore Dermatology, Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 199. Encore Dermatology, Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 200. Encore Dermatology, Inc. Recent Developments
Table 201. LEO Pharma Corporation Information
Table 202. LEO Pharma Description and Major Businesses
Table 203. LEO Pharma Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 204. LEO Pharma Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 205. LEO Pharma Recent Developments
Table 206. Almirall, S.A Corporation Information
Table 207. Almirall, S.A Description and Major Businesses
Table 208. Almirall, S.A Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 209. Almirall, S.A Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 210. Almirall, S.A Recent Developments
Table 211. Aclaris Therapeutics, Inc. Corporation Information
Table 212. Aclaris Therapeutics, Inc. Description and Major Businesses
Table 213. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 214. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 215. Aclaris Therapeutics, Inc. Recent Developments
Table 216. Taro Pharmaceutical Industries Ltd. Corporation Information
Table 217. Taro Pharmaceutical Industries Ltd. Description and Major Businesses
Table 218. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 219. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 220. Taro Pharmaceutical Industries Ltd. Recent Developments
Table 221. Teligent Pharma Corporation Information
Table 222. Teligent Pharma Description and Major Businesses
Table 223. Teligent Pharma Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 224. Teligent Pharma Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 225. Teligent Pharma Recent Developments
Table 226. Perrigo Pharma Corporation Information
Table 227. Perrigo Pharma Description and Major Businesses
Table 228. Perrigo Pharma Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 229. Perrigo Pharma Semi-Solid Dosage Form Product Model Numbers, Pictures, Descriptions and Specifications
Table 230. Perrigo Pharma Recent Developments
Table 231. Key Raw Materials Lists
Table 232. Raw Materials Key Suppliers Lists
Table 233. Semi-Solid Dosage Form Distributors List
Table 234. Semi-Solid Dosage Form Customers List
Table 235. Semi-Solid Dosage Form Market Trends
Table 236. Semi-Solid Dosage Form Market Drivers
Table 237. Semi-Solid Dosage Form Market Challenges
Table 238. Semi-Solid Dosage Form Market Restraints
Table 239. Research Programs/Design for This Report
Table 240. Key Data Information from Secondary Sources
Table 241. Key Data Information from Primary Sources
List of Figures
Figure 1. Semi-Solid Dosage Form Product Picture
Figure 3. Global Semi-Solid Dosage Form Market Share by Type in 2021 & 2028
Figure 3. Ointments Product Picture
Figure 4. Gels Product Picture
Figure 5. Others Product Picture
Figure 6. Global Semi-Solid Dosage Form Market Share by Application in 2021 & 2028
Figure 7. Skin
Figure 8. Nasal Cavity
Figure 9. Vaginal Cavity
Figure 10. Rectal Cavity
Figure 11. Others
Figure 12. Semi-Solid Dosage Form Report Years Considered
Figure 13. Global Semi-Solid Dosage Form Sales 2017-2028 (K Units)
Figure 14. Global Semi-Solid Dosage Form Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Semi-Solid Dosage Form Revenue 2017-2028 (US$ Million)
Figure 16. Global Semi-Solid Dosage Form Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Semi-Solid Dosage Form Sales Market Share by Region (2017-2022)
Figure 18. Global Semi-Solid Dosage Form Sales Market Share by Region (2023-2028)
Figure 19. North America Semi-Solid Dosage Form Sales YoY (2017-2028) & (K Units)
Figure 20. North America Semi-Solid Dosage Form Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Semi-Solid Dosage Form Sales YoY (2017-2028) & (K Units)
Figure 22. Europe Semi-Solid Dosage Form Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Semi-Solid Dosage Form Sales YoY (2017-2028) & (K Units)
Figure 24. Asia-Pacific Semi-Solid Dosage Form Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Semi-Solid Dosage Form Sales YoY (2017-2028) & (K Units)
Figure 26. Latin America Semi-Solid Dosage Form Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Semi-Solid Dosage Form Sales YoY (2017-2028) & (K Units)
Figure 28. Middle East & Africa Semi-Solid Dosage Form Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Semi-Solid Dosage Form Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Semi-Solid Dosage Form in the World: Market Share by Semi-Solid Dosage Form Revenue in 2021
Figure 31. Global Semi-Solid Dosage Form Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
Figure 33. Global Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
Figure 34. Global Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
Figure 35. Global Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
Figure 36. North America Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
Figure 37. North America Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
Figure 38. North America Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
Figure 39. North America Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
Figure 40. North America Semi-Solid Dosage Form Sales Share by Country (2017-2028)
Figure 41. North America Semi-Solid Dosage Form Revenue Share by Country (2017-2028)
Figure 42. U.S. Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
Figure 45. Europe Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
Figure 46. Europe Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
Figure 47. Europe Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
Figure 48. Europe Semi-Solid Dosage Form Sales Share by Country (2017-2028)
Figure 49. Europe Semi-Solid Dosage Form Revenue Share by Country (2017-2028)
Figure 50. Germany Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 51. France Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Semi-Solid Dosage Form Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Semi-Solid Dosage Form Revenue Share by Region (2017-2028)
Figure 61. China Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 64. India Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 66. Taiwan Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 70. Philippines Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 71. Latin America Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
Figure 72. Latin America Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
Figure 73. Latin America Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
Figure 74. Latin America Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
Figure 75. Latin America Semi-Solid Dosage Form Sales Share by Country (2017-2028)
Figure 76. Latin America Semi-Solid Dosage Form Revenue Share by Country (2017-2028)
Figure 77. Mexico Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 78. Brazil Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 79. Argentina Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 80. Middle East and Africa Semi-Solid Dosage Form Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Semi-Solid Dosage Form Revenue Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Semi-Solid Dosage Form Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Semi-Solid Dosage Form Revenue Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Semi-Solid Dosage Form Sales Share by Country (2017-2028)
Figure 85. Middle East and Africa Semi-Solid Dosage Form Revenue Share by Country (2017-2028)
Figure 86. Turkey Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 87. Saudi Arabia Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 88. UAE Semi-Solid Dosage Form Revenue (2017-2028) & (US$ Million)
Figure 89. Semi-Solid Dosage Form Value Chain
Figure 90. Semi-Solid Dosage Form Production Process
Figure 91. Channels of Distribution
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed